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Jane A. Cannon, MB, CHB, John J.V. McMurray, MDT here are few if any conditions that involve asmany organs as heart failure (HF). Clinicianssee lung, kidney, liver, brain, and skeletal
muscle involvement on a day-to-day basis when
managing patients with HF. For some years, the gut
has also been implicated in HF. Speciﬁcally, it has
been suggested that intestinal edema and ischemia
may lead to increased gut permeability and entry
of lipopolysaccharides produced by gram-negative
bacteria into the circulation (1–3). These, in turn, are
thought to activate cytokines and generate systemic
inﬂammation that may contribute to pathophysiolog-
ical progression of the HF syndrome. These mecha-
nisms are believed to be most operative in patients
with congestion and cachexia (1–3).SEE PAGE 1908In this issue of the Journal, Tang et al. (4) reported
new intestinal ﬁndings in HF. In a substantial
observational study, these researchers found that
plasma trimethylamine-N-oxide (TMAO) levels were
increased in patients with HF undergoing coronary
angiography (n ¼ 720) compared with healthy con-
trols (n ¼ 300). TMAO, an amine oxide, is ultimately
derived from foods containing L-carnitine (such as
red meat) or phosphatidylcholine (lecithin), the
main dietary source of choline (found in eggs).
Choline is metabolized by gut bacteria to produce the
intermediate compound trimethylamine (TMA),
which freely enters the circulation and is then
oxidized by hepatic ﬂavin monooxygenases (in
particular FMO3) to form TMAO. TMAO is excreted
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ease has been proposed as a result of its action on
cholesterol transport, macrophage activity, and
possibly other atherogenic mechanisms (5,6). Now,
Tang et al. (4) suggest a pathophysiological role of
TMAO (and by implication intestinal microbiota) in
HF. Not only were TMAO levels increased in patients
with HF but higher levels were associated with
adverse prognostic features (e.g., older age, diabetes,
renal impairment, higher B-type natriuretic peptide
concentrations) and reduced survival. Moreover,
TMAO remained a predictor of mortality even
when adjustments were made for other prognostic
variables.
How should we interpret these ﬁndings, and can
they be tied in to the original “gut hypothesis” of HF?
From what we know about TMAO, the likely expla-
nations for increased plasma levels in HF are
increased TMA production in the bowel (reﬂecting
diet and the composition of the intestinal micro-
biota), increased TMA entry from the bowel to blood
(signaling intestinal barrier function), increased FMO
activity, or decreased clearance of TMAO from the
plasma compartment (or some combination of these).
It would be of interest in future studies to know more
about diet and use of drugs that might affect in-
testinal microbiota such as antibiotics and acid-
suppressing agents.
There is prior evidence that gut ﬂora may be
altered in HF (1–3). Previous studies also described
increased intestinal permeability in HF, although in
the present study, high-sensitivity C-reactive protein
levels were not greater in the higher TMAO group.
Moreover, congestion and right-sided hemodynamics
were not reported, and overall use of loop diuretics
was low (although somewhat greater in the higher
TMAO group) (1–3). In other words, the patients
with higher TMAO levels did not fully ﬁt the
proﬁle of those previously described as most likely
to have increased intestinal permeability. Future
studies might also report on liver function, hepatic
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1916congestion, or use of drugs that might have inﬂu-
enced FMO activity.
In addition, the strong correlation between TMAO
concentration and kidney function raises the following
question: given the importance of the kidney in elim-
inating TMAO, is higher TMAO level just a marker
of renal impairment (7)? Other questions arise—for
example, what is the role of comorbidities, such as
diabetes, in elevating TMAO levels? Diabetes was con-
siderably more common in the higher TMAO group,
and metformin has been reported to increase TMAO
levels (and intestinal microbiota have been postulated
to play a role in the development of diabetes) (6,8).
More puzzling is just how TMAO by itself might
relate to prognosis. It is probably unlikely that aproatherogenic mechanism could account for an in-
crease in mortality in such a short time frame, espe-
cially in patients with nonobstructive coronary
disease. As we know, the majority of deaths in such
patients will have likely been due to pump failure or
an arrhythmia, not coronary events. Clearly, this
is only the beginning of the story of TMAO in HF
but one for which we should look forward to further
installments.
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